414 related articles for article (PubMed ID: 37153571)
1. Biomaterials promote
Qin YT; Li YP; He XW; Wang X; Li WY; Zhang YK
Front Immunol; 2023; 14():1165576. PubMed ID: 37153571
[TBL] [Abstract][Full Text] [Related]
2. Biomaterials for chimeric antigen receptor T cell engineering.
Niu H; Zhao P; Sun W
Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
[TBL] [Abstract][Full Text] [Related]
3. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
4. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment.
Lin Y; Chen Y; Luo Z; Wu YL
Nanoscale; 2024 Feb; 16(7):3226-3242. PubMed ID: 38284230
[TBL] [Abstract][Full Text] [Related]
7. Advanced Materials and Delivery Systems for Enhancement of Chimeric Antigen Receptor Cells.
Li T; Luo R; Su L; Lv F; Mei L; Yu Y
Small Methods; 2023 Nov; 7(11):e2300880. PubMed ID: 37653606
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
Zhang C; Zhuang Q; Liu J; Liu X
ACS Synth Biol; 2022 Jan; 11(1):1-15. PubMed ID: 35005887
[TBL] [Abstract][Full Text] [Related]
10. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel KE; Fricke S; Köhl U; Schmiedel D
Front Immunol; 2022; 13():822298. PubMed ID: 35371071
[TBL] [Abstract][Full Text] [Related]
11. Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.
Yu T; Yu SK; Xiang Y; Lu KH; Sun M
Front Immunol; 2022; 13():936496. PubMed ID: 35903099
[TBL] [Abstract][Full Text] [Related]
12. Current Challenges and Strategies for Chimeric Antigen Receptor-T-Cell Therapy for Solid Tumors.
Chen J; Jiang H
Crit Rev Immunol; 2021; 41(1):1-12. PubMed ID: 33822521
[TBL] [Abstract][Full Text] [Related]
13. CAR-T Cell Therapy: Challenges and Optimization.
Luo M; Zhang H; Zhu L; Xu Q; Gao Q
Crit Rev Immunol; 2021; 41(1):77-87. PubMed ID: 33822526
[TBL] [Abstract][Full Text] [Related]
14. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
15. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.
Wang L; Yao R; Zhang L; Fan C; Ma L; Liu J
Int Immunopharmacol; 2019 May; 70():498-503. PubMed ID: 30875561
[TBL] [Abstract][Full Text] [Related]
16. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
17. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
[TBL] [Abstract][Full Text] [Related]
18. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
19. Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors: A Narrative Review.
Hauth F; Ho AY; Ferrone S; Duda DG
JAMA Oncol; 2021 Jul; 7(7):1051-1059. PubMed ID: 33885725
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]